BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 246 filers reported holding BIO-TECHNE CORP in Q3 2015. The put-call ratio across all filers is 1.94 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $651,000 | +16.2% | 5,542 | +0.7% | 0.08% | +15.4% |
Q1 2017 | $560,000 | +5.5% | 5,505 | +6.7% | 0.06% | -1.5% |
Q4 2016 | $531,000 | -8.8% | 5,161 | -2.9% | 0.07% | -14.3% |
Q3 2016 | $582,000 | +2.3% | 5,315 | +5.4% | 0.08% | -2.5% |
Q2 2016 | $569,000 | +19.0% | 5,045 | -0.3% | 0.08% | +16.2% |
Q1 2016 | $478,000 | +27.5% | 5,062 | +21.5% | 0.07% | +19.3% |
Q4 2015 | $375,000 | -14.6% | 4,166 | -12.4% | 0.06% | -18.6% |
Q3 2015 | $439,000 | +4.8% | 4,753 | +11.6% | 0.07% | +12.9% |
Q2 2015 | $419,000 | -10.7% | 4,258 | -9.0% | 0.06% | -10.1% |
Q1 2015 | $469,000 | +10.1% | 4,678 | +1.4% | 0.07% | +13.1% |
Q4 2014 | $426,000 | – | 4,614 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $13,206,000 | 5.33% |
Montanaro Asset Management Ltd | 101,950 | $28,954,000 | 4.43% |
Jackson Square Partners, LLC | 521,991 | $148,245,000 | 3.89% |
Sandhill Capital Partners LLC | 119,671 | $33,987,000 | 3.88% |
STONE RUN CAPITAL, LLC | 22,055 | $6,264,000 | 3.38% |
Ownership Capital B.V. | 610,466 | $173,372,000 | 3.35% |
Brown Capital Management | 823,303 | $233,818,000 | 3.28% |
DF DENT & CO INC | 671,348 | $190,663,000 | 2.94% |
Westwind Capital | 27,931 | $7,932,000 | 2.78% |
MAIRS & POWER INC | 673,620 | $191,308,000 | 2.41% |